A Study of HRS-7535 Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequately Controlled With Metformin

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 810 participants.

Also called NCT06589765

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 810 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT06589765
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT06589765. Randomized; double masking; primary purpose treatment. Start 2024-09-27 (actual); primary completion 2026-05-29 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of HRS-7535 Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequately Controlled With Metformin
Intervention (Drug)
HRS-7535 tablet
Intervention (Drug)
dapagliflozin tablet
Lead sponsor
Shandong Suncadia Medicine Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct06589765
Content hash
6046d4abc3e6c0e9759426fccf28b064270af7c47932418aafb9a900160a1799